The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation
Launched by CHULALONGKORN UNIVERSITY · Jan 11, 2017
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
Septic shock (SS) is globally prevalent in with high mortality rate.The current focuses on initial treatment of this condition emphasize on the early recognition, prompt administration of antibiotic, and restoration of hemodynamic with aggressive fluid resuscitation and vasopressor. Regarding the initial fluid therapy, administration of empirical crystalloid at the dose of 30 ml/kg is recommended in the guideline. The ultrasound-assisted management of shock patients has been introduced in the past decade and now is widely used. By using the measurement of inferior vena cava (IVC) diameter c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient who attended the emergency department with septic shock (defined by those who require a vasopressor to maintain a mean arterial pressure (MAP) of 65 mm Hg or greater and whose serum lactate level greater than 2 mmol/L in the absence of hypovolemia.)
- Exclusion Criteria:
- • 1) Congestive pulmonary edema or known to have poor systolic cardiac function (left ventricular ejection fraction ≤ 40%).
- • 2) Known to have right heart pathologies.
- • 3) Having or suspected to have marked ascites, significant bowel dilatation or the conditions that can cause abdominal hypertension.
- • 4) Body mass index ≥ 30 kg/square meter.
- • 5) Having concomitant attack of severe airway disease (eg. Asthma, COPD) that may have confounded the IVC interpretation due to the positive intrathoracic pressure.
- • 6) IVC can not be identified or its diameter cannot be measured correctly.
- • 7) Having end-stage renal diseases with or without dialysis.
- • 8) Having non-infectious diseases as final diagnoses.
- • 9) Pregnant women.
- • 10) Have been referred or treated from other healthcare facility.
- • 11) Having active hemorrhages.
- • 12) Duplicated cases.
- • 13) who had "do-not-resuscitate" living will.
- • 14) Declined to consent.
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pathum Wan, Bangkok, Thailand
Patients applied
Trial Officials
Khrongwong Musikatavorn, MD
Principal Investigator
Emergency Unit, Faculty of Medicine, Chulalongkorn Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials